(R)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine | 1174565-35-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
• 英文别名: (2R)-2-{2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine；(2R)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
• CAS: 1174565-35-5
• 化学式: C₂₁H₂₆ClNO
• 分子量: 343.897
• InChiKey: YNNUSGIPVFPVBX-VQCQRNETSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine 以 乙醇 、 正己烷 、 二乙胺 为溶剂， 生成 富马酸氯马斯汀
  参考文献：
  名称：

  SUBSTITUTED BENZHYDRYLETHERS

  摘要：

  本文揭示了式I的取代苯基乙醚，其制备方法，药物组合物以及它们的使用方法。

  公开号：

  US20090203763A1
• 作为产物：
  描述：

  (R)-2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride 、 1-(4-氯苯基)-1-苯基乙醇 在 sodium amide 作用下， 以 甲苯 为溶剂， 反应 8.0h， 以36%的产率得到(R)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
  参考文献：
  名称：

  SUBSTITUTED BENZHYDRYLETHERS

  摘要：

  本文揭示了式I的取代苯基乙醚，其制备方法，药物组合物以及它们的使用方法。

  公开号：

  US20090203763A1

文献信息

• Methods and compositions for treating degenerative and ischemic disorders
  申请人：The General Hospital Corporation

  公开号：US10322122B2

  公开（公告）日：2019-06-18

  Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.

  模型系统显示，将细胞对氧化磷酸化（OXPHOS）的依赖转移到糖酵解，可以防止细胞死亡。然而，由于缺乏重塑能量代谢的临床安全药物，这一策略的治疗潜力一直受到限制。本发明确定了能够调节氧化代谢的无毒小分子（如药物样化合物）。其中一种已确定的化合物包括麦考嗪。如本文所述，麦考嗪及其对映体 S-麦考嗪可将 OXPHOS 重定向至糖酵解。这类化合物对退化性疾病，如糖尿病、亨廷顿氏病、帕金森氏病和阿尔茨海默氏症和/或缺血性疾病，包括但不限于中风、心脏病发作或再灌注损伤具有保护或治疗作用。
• METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS
  申请人：The General Hospital Corporation

  公开号：US20180071279A1

  公开（公告）日：2018-03-15

  Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.
• EUTECTIC SOLVENTS COMPRISING PHARMACEUTICAL AGENTS, AND METHODS OF MAKING AND USE THEREOF
  申请人：Novilla Pharmaceuticals, Inc.

  公开号：US20210308048A1

  公开（公告）日：2021-10-07

  The present invention generally relates to eutectic compositions comprising pharmaceutical agents and other beneficial substances, and in particular, to eutectic compositions where the pharmaceutical agent and beneficial substance forms a part of the eutectic composition. In one aspect, the pharmaceutical agent and beneficial substance defines part of the eutectic composition, i.e., rather than just being present within the eutectic composition. In one set of embodiments, at least about 20 mol % of the eutectic composition may comprise a hydrogen bond donor and a hydrogen bond acceptor, for example, acetaminophen and choline chloride, respectively. However, in other embodiments, the pharmaceutical agent can be either donor or acceptor, and the other agent either donor or acceptor. Other aspects are generally directed to methods of making such compositions, methods of using such compositions, kits including such compositions, etc.
• US9925202B2
  申请人：——

  公开号：US9925202B2

  公开（公告）日：2018-03-27
• [EN] SUBSTITUTED BENZHYDRYLETHERS<br/>[FR] BENZHYDRYLÉTHERS SUBSTITUÉS
  申请人：AUSPEX PHARMACEUTICALS

  公开号：WO2009094457A2

  公开（公告）日：2009-07-30

  Disclosed herein are substituted benzhydrylethers of Formula (I), processes of preparation thereof, pharmaceutical compositions thereof, and methods of their use therof.